Clinical Trials Logo

Clinical Trial Summary

A study to investigate feasibility of local selection of patients with squamous cell carcinoma of the pharynx or larynx using anticipated benefit of proton radiotherapy in reducing the risk of late dysphagia or xerostomia.


Clinical Trial Description

In preparation for a randomised study in Denmark (DAHANCA 35) the feasibility of selecting newly diagnosed patients with squamous cell carcinoma of the pharynx or larynx for proton therapy at the local treatment centers is investigated. A proton and a photon doseplan is prepared for patients planned for primary radiotherapy . If proton radiotherapy reduces the anticipated absolute risk of dysphagia >= grade 2 (DAHANCA scale and/or xerostomia >= grade 2 (EORTC Head-Neck 35) with a clinical relevant value the patient is offered proton therapy at the Danish Center for Particle Therapy. The anticipated risk of xerostomia and dysphagia is estimated using Normal-Tissue Complication Models (NTCP). At least five patients from each of the six Danish centers are required in this feasibility study. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05423704
Study type Interventional
Source Danish Head and Neck Cancer Group
Contact
Status Active, not recruiting
Phase N/A
Start date May 20, 2019
Completion date May 14, 2026

See also
  Status Clinical Trial Phase
Recruiting NCT04607694 - DAHANCA 35: Proton Versus Photon Therapy for Head-neck Cancer N/A
Completed NCT02776137 - Postoperative Concurrent Chemoradiotherapy With Docetaxel for High-Risk Squamous Cell Carcinoma of Head and Neck Phase 2
Recruiting NCT03552458 - Effects of Probiotics in Preventing Oral Mucositis Phase 2
Recruiting NCT02238587 - The Effect of Ganoderma on Patients With Head-and-neck Cancer N/A
Enrolling by invitation NCT04257968 - Long Term Complications in Head and Neck Cancer Patients N/A
Recruiting NCT02764216 - Elective Mucosal Irradiation in Head-and-Neck Cancer of Unknown Primary Phase 2